ReviewMolecular biology reports2025
The role and therapeutic potential of exosome-mediated microRNAs regulatory networks in diabetic kidney disease.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Urinary Extracellular Vesicle-Derived miRNAs as Regulators and Biomarkers in Diabetic Kidney Disease.International journal of molecular sciences · 2026Review
- From pathogenic carriers to therapeutic hope: the dual role and translational prospects of exosomes in diabetic kidney disease.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Diabetic kidney disease (DKD), a leading cause of end-stage renal disease, involves complex pathological mechanisms such as inflammation, fibrosis, oxidative stress, and immune dysregulation. Exosome-mediated microRNAs (miRNAs), as stable carriers of genetic material in body fluids, have emerged as crucial regulators of DKD progression by modulating intercellular communication and gene expression. This review summarizes the biogenesis and regulatory mechanisms of exosome-encapsulated miRNAs, highlighting their roles in glomerular injury, tubulointerstitial fibrosis, and immunoinflammatory responses in DKD. Specific exosomal miRNAs, including miR-21, miR-29, miR-192, and miR-155, are discussed for their contributions to renal cell injury and fibrotic progression. Moreover, exosomal miRNAs demonstrate significant potential as noninvasive biomarkers for early DKD diagnosis and disease monitoring, given their stability and tissue-specific expression profiles. Therapeutically, interventions targeting pathogenic miRNAs or delivering protective miRNAs via engineered exosomes offer promising strategies for DKD treatment. Despite current challenges related to standardization, delivery efficiency, and safety, advances in exosome engineering and nucleic acid therapeutics are expected to accelerate the clinical translation of exosomal miRNA-based precision medicine in DKD.
Indexed as
Identifiers
40944788What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.